Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

AC Immune S.A. (ACIU)

AC Immune S.A. (ACIU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AC Immune: Q3 Earnings Snapshot

AC Immune: Q3 Earnings Snapshot

ACIU : 3.35 (+1.82%)
AC Immune: Q2 Earnings Snapshot

AC Immune: Q2 Earnings Snapshot

ACIU : 3.35 (+1.82%)
AC Immune: Q1 Earnings Snapshot

AC Immune: Q1 Earnings Snapshot

ACIU : 3.35 (+1.82%)
AC Immune: Q3 Earnings Snapshot

AC Immune: Q3 Earnings Snapshot

ACIU : 3.35 (+1.82%)
AC Immune: Q2 Earnings Snapshot

AC Immune: Q2 Earnings Snapshot

ACIU : 3.35 (+1.82%)
Why Shares of AC Immune Jumped This Week

The FDA has granted a Fast Track Designation to its Alzheimer's disease vaccine candidate.

ACIU : 3.35 (+1.82%)
AC Immune: Q1 Earnings Snapshot

AC Immune: Q1 Earnings Snapshot

ACIU : 3.35 (+1.82%)
Is Ardelyx is A Buy After Slip in Early 2022

Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them

ARDX : 5.25 (+2.54%)
CNCE : 8.37 (+0.12%)
KYKOF : 16.7472 (+0.41%)
SFOSF : 2.0000 (-6.54%)
KHTRF : 3.7300 (+1.00%)
ACIU : 3.35 (+1.82%)
BMEA : 6.47 (+1.41%)
AC Immune: Q3 Earnings Snapshot

AC Immune: Q3 Earnings Snapshot

ACIU : 3.35 (+1.82%)
Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC

Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences...

ACIU : 3.35 (+1.82%)

Barchart Exclusives

Attention Long-Time SoFi Technologies Shareholders: Thursday's Unusual Options Activity Could Guide Your Next Investment Move
Title: Summary: SoFi Technologies had the third-highest Vol/OI ratio in Thursday’s options trading. It was one of 20 unusually active options for the fintech growth stock. If you bought SOFI stock at the 2022 lows, it could be time to get protective. $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ A couple of interesting economic data points... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar